BiotechTube

clobetasol propionate

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hand Dermatosis

Conditions

Hand Dermatosis

Trial Timeline

Oct 1, 2008 → Jan 1, 2009

NCT ID
NCT00828464

About clobetasol propionate

clobetasol propionate is a approved stage product being developed by GSK plc for Hand Dermatosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00828464. Target conditions include Hand Dermatosis.

What happened to similar drugs?

0 of 9 similar drugs in Hand Dermatosis were approved

Approved (0) Terminated (2) Active (7)
🔄Lebrikizumab + PlaceboEli LillyPhase 3
🔄Pimecrolimus Cream 1%NovartisPhase 3
🔄tocilizumab + saline solutionRochePhase 3
🔄dupilumab + PlaceboSanofiPhase 3
❌Ruxolitinib cream + VehicleIncytePhase 3
❌Ruxolitinib cream + VehicleIncytePhase 3
🔄alitretinoinBasilea PharmaceuticaPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00828464ApprovedCompleted

Competing Products

17 competing products in Hand Dermatosis

See all competitors
ProductCompanyStageHype Score
Lebrikizumab + PlaceboEli LillyPhase 3
44
Methylprednisolone TabletJohnson & JohnsonPhase 2/3
34
ABT-981 + Placebo for ABT-981AbbViePhase 2
35
Pimecrolimus Cream 1%NovartisPhase 3
40
tocilizumab + saline solutionRochePhase 3
40
denosumab + PlaceboAmgenPhase 2
35
Dupilumab + PlaceboSanofiPhase 2
31
dupilumab + PlaceboSanofiPhase 3
40
urea 40% cream + fluocinonide 0.05% cream + tazarotene 0.1% cream + bland emollient cream (Udderly smooth® Udder Cream)BayerPhase 2
24
Ruxolitinib cream + VehicleIncytePhase 3
29
Ruxolitinib cream + VehicleIncytePhase 2
32
RuxolitinibIncytePhase 1/2
29
Ruxolitinib cream + VehicleIncytePhase 3
29
ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle CreamArcutis BiotherapeuticsPhase 1/2
26
alitretinoinBasilea PharmaceuticaPhase 3
34
alitretinoinBasilea PharmaceuticaPhase 3
34
alitretinoinBasilea PharmaceuticaPhase 3
34